Literature DB >> 15931673

Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis.

Tiina M Kauppinen1, Sang Won Suh, Claude P Genain, Raymond A Swanson.   

Abstract

Multiple sclerosis (MS) is an immune-mediated disabling neurological disorder involving inflammation, demyelination, axonal damage, and neurodegeneration. Poly(ADP-ribose)polymerase-1 (PARP-1), a nuclear enzyme linked to DNA repair, has been shown to regulate the cellular inflammatory response through interactions with nuclear factor-kappaB. Extensive PARP-1 activation can, by separate mechanisms, also cause cell death. PARP-1 activation in brain occurs in several settings associated with oxidative stress and DNA damage, and PARP-1 inhibition has been shown to attenuate inflammation and improve neuronal survival in these settings. Here we studied the pattern of PARP-1 activation in a nonhuman primate model of MS, marmoset (Callithrix jacchus) experimental allergic encephalomyelitis (EAE). Characteristic of this model is relapsing and remitting focal demyelination typical of human MS. Immunostaining for poly(ADP-ribose), the enzymatic product of PARP-1, showed PARP-1 activation specifically in plaque areas of EAE brains. Robust immunostaining was found in astrocytes surrounding demyelinated EAE plaques and in scattered nearby microglia, oligodendrocytes, and neurons. The immunostaining also suggested PARP-1 activation in occasional endothelial cells surrounded by microglia or infiltrating peripheral blood cells. Given the importance of PARP-1 in both inflammation and cell death processes, these findings suggest that PARP-1 activation may be a significant factor in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931673     DOI: 10.1002/jnr.20525

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  19 in total

1.  Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2.

Authors:  Tiina M Kauppinen; Wai Y Chan; Sang Won Suh; Amanda K Wiggins; Eric J Huang; Raymond A Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

2.  Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.

Authors:  L Cavone; B Peruzzi; R Caporale; A Chiarugi
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 3.  NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns.

Authors:  Hassina Massudi; Ross Grant; Gilles J Guillemin; Nady Braidy
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

Review 4.  PARP overactivation in neurological disorders.

Authors:  Vijay Kumar Arruri; Chayanika Gundu; Islauddin Khan; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Mol Biol Rep       Date:  2021-03-25       Impact factor: 2.316

Review 5.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

6.  PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.

Authors:  Vimal Selvaraj; Mangala M Soundarapandian; Olga Chechneva; Ambrose J Williams; Maxim K Sidorov; Athena M Soulika; David E Pleasure; Wenbin Deng
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

Review 7.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 8.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 9.  NAD+ and NADH in neuronal death.

Authors:  Weihai Ying
Journal:  J Neuroimmune Pharmacol       Date:  2007-02-10       Impact factor: 4.147

10.  A comparative evaluation of the response to peroxynitrite by a brain endothelial cell line and control of the effects by drug targeting.

Authors:  Christopher Bolton; Elizabeth G Wood; Gwen S Scott; Roderick J Flower
Journal:  Cell Mol Neurobiol       Date:  2009-03-28       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.